Obeticholic acid 5mg Tablets

Obeticholic acid 5mg Tablets represent a significant advancement in the therapeutic management of chronic cholestatic liver diseases, specifically Primary Biliary Cholangitis (PBC). As a first-in-class potent and selective farnesoid X receptor (FXR) agonist, this medication addresses the underlying pathology of cholestasis through a novel mechanism.

The FXR is a nuclear receptor expressed heavily in the liver and intestine, serving as a critical regulator of bile acid, lipid, and glucose homeostasis. In patients with PBC, bile ducts become inflamed and destroyed, leading to a toxic buildup of bile acids in the liver (cholestasis), which causes further liver damage, fibrosis, and potentially cirrhosis.

Obeticholic acid 5mg Tablets work by binding to and activating the FXR, which triggers a cascade of downstream effects. Primarily, it inhibits the enzyme cholesterol 7-alpha-hydroxylase (CYP7A1)—the rate-limiting step in bile acid synthesis—thereby reducing the production of bile acids from cholesterol. Simultaneously, it increases the expression of transporters that facilitate the export of bile acids out of the liver cells. This dual action of decreasing synthesis and promoting clearance effectively lowers the toxic bile acid burden on the liver, slows disease progression, and improves liver biochemical markers.

Indications / Uses of Obeticholic acid 5mg Tablets

Obeticholic acid 5mg Tablets are indicated for the treatment of specific adult populations suffering from progressive liver conditions where first-line therapies have proven insufficient or intolerant. The primary indications include:

• Primary Biliary Cholangitis (PBC) Combination Therapy: It is indicated for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA monotherapy. This combination provides a synergistic effect to lower alkaline phosphatase (ALP) levels.
• Primary Biliary Cholangitis (PBC) Monotherapy: For adult patients who are unable to tolerate UDCA due to side effects, Obeticholic acid 5mg Tablets serve as an effective monotherapy option to manage the disease.
• Reduction of Liver Enzyme Levels: The medication is prescribed to achieve a sustained reduction in ALP and total bilirubin, key biomarkers associated with the risk of liver transplant and mortality in PBC patients.
• Cholestasis Management: By regulating bile acid homeostasis, it helps manage the chronic cholestasis that characterizes the disease, aiming to preserve liver function and delay the onset of fibrosis and cirrhosis.

Key Features

• Targeted FXR Agonist: Unlike non-specific therapies, this drug selectively targets the farnesoid X receptor, directly modulating the genetic pathways responsible for bile acid synthesis and transport.
• Potent Bile Acid Reduction: It is highly effective at reducing the intracellular concentration of toxic bile acids, which are the primary drivers of hepatocyte injury in cholestatic diseases.
• Once-Daily Oral Dosing: The medication is formulated as a tablet for once-daily administration, simplifying the treatment regimen for patients managing a chronic condition.
• Titratable Dosage: The 5mg tablet allows for a safe starting dose, which can be titrated up to 10mg based on tolerability and therapeutic response, allowing for personalized treatment plans.
• Proven Efficacy in Non-Responders: Clinical trials have demonstrated its ability to significantly improve liver biochemistry in patients who have failed to achieve adequate results with standard UDCA therapy.

Storage for Obeticholic acid 5mg Tablets

To ensure the pharmacological stability and safety of Obeticholic acid 5mg Tablets, proper storage conditions must be maintained. The medication should be stored at controlled room temperature, specifically between 20°C and 25°C (68°F to 77°F). Brief excursions are permitted between 15°C and 30°C (59°F to 86°F). It is crucial to keep the tablets in their original container to protect them from moisture and humidity, which can affect the drug’s integrity. Do not store the medication in bathrooms or near sinks. Always keep the container tightly closed and store it in a secure location, out of the reach and sight of children and pets.

Important Note on Obeticholic acid 5mg Tablets

Treatment with Obeticholic acid 5mg Tablets requires strict adherence to dosing guidelines and careful medical supervision, particularly regarding liver function. The starting dose is typically 5mg once daily, which may be increased to 10mg after months of treatment if the patient is tolerating the drug well but has not achieved an adequate reduction in ALP and/or total bilirubin.

A critical warning involves the risk of hepatic decompensation and failure in patients with incorrect dosing, particularly those with moderate to severe hepatic impairment (Child-Pugh B or C). For these patients, the dosing frequency must be drastically reduced (e.g., 5mg once weekly), and monitoring must be intensified. Incorrect dosing in these populations has led to liver failure and death.

Pruritus (severe itching) is the most common side effect and can be dose-limiting; strategies to manage this include adding bile acid sequestrants, antihistamines, or dose reduction. Lipid profile changes, such as a decrease in HDL-C (“good” cholesterol), have also been observed, necessitating regular monitoring of lipid levels. Patients should take the tablet with or without food but should separate it from bile acid binding resins (like cholestyramine) by at least 4 to 6 hours. Report any signs of worsening liver function (e.g., jaundice, ascites, confusion) immediately.